To influence treatment choice and control expenditures, insurance plans impose cost sharing policies for expensive oral tyrosine kinase inhibitors (TKIs). We evaluated the effect of patient TKI copayments on insurance expenditures among patients with EGFR and ALK positive advanced NSCLC receiving TKIs. The results show that higher TKI copayments were not associated with lower insurance expenditures. Eliminating TKI copayments would reduce patient financial burden and not adversely impact insurer spending. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.1256
Authors: B. Haddock Lobo Goulart, S. Chennupati, K. Egan, C. Fedorenko, S. Ramsey